KRAS and neoplasm: However, unlike in our study, they did not provide the QALY gained and ICER of anti-EGFR mAb compared to Bev in different scenarios of KRAS WT, pan-RAS WT, and pan-RAS left-sided tumor population to justify their conclusion (39).